natgillin/translations-raw huggingface dataset:
An extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly zoledronic acid over the 12-month extension treatment period in children who had completed one year of treatment with either zoledronic acid or pamidronate in the core study. 
12-mjesečnog produžetka terapijskog razdoblja u djece koja su dovršila godinu dana liječenja zoledronatnom kiselinom ili pamidronatom u glavnom ispitivanju.
In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients that were given zoledronic acid as indicated in sections 4.1 and 4.2. 
U razdoblju nakon stavljanja lijeka u promet u bolesnika koji su uzimali zoledronatnu kiselinu sukladno navedenom u dijelovima 4.1 i 4.2 zabilježeni su jaki i ponekad onesposobljavajući bolovi u kostima, zglobovima i/ili mišićima.
The hydration status of patients must be assessed prior to and following administration of Zoledronic acid Actavis to ensure that they are adequately hydrated. 
Prije i poslije primjene Zoledronatne kiseline Actavis mora se provjeriti status hidracije bolesnika kako bi se osiguralo da su primjereno hidrirani.
Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating Zoledronic acid Actavis therapy. 
Nakon početka terapije Zoledronatnom kiselinom Actavis potrebno je pažljivo pratiti standardne metaboličke parametre hiperkalcemije, kao što su razine kalcija, fosfata i magnezija u serumu.
- 4.1 ml for 3.3 mg dose 
- 4,4 ml za dozu od 3,5 mg - 4,1 ml za dozu od 3,3 mg - 3,8 ml za dozu od 3,0 mg
Zoledronic acid Actavis 4 mg/5 ml sterile concentrate zoledronic acid 
Zoledronatna kiselina Actavis 4 mg/5 ml sterilni koncentrat zoledronatna kiselina i.v.
Rare (may affect up to 1 in 1,000 people): - As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia). 
Kao posljedica niskih razina kalcija: nepravilni otkucaji srca (srčana artimija, uslijed hipokalcemije).
You must not be given Zoledronic acid Actavis if you are breast-feeding. 
Ne smijete primati Zoledronatnu kiselinu Actavis ako dojite.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes. 
100 ml (vidjeti dio 6.6), potrebno je dati kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion 
Zoledronatna kiselina Actavis 4 mg/5 ml koncentrat za otopinu za infuziju
How to store Zoledronic acid Actavis 
Kako primjenjivati Zoledronatnu kiselinu Actavis
Acute renal failure, haematuria, proteinuria Acquired Fanconi syndrome 
Akutno zatajenje bubrega, hematurija, proteinurija
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion zoledronic acid 
Zoledronatna kiselina Actavis 4 mg/5 ml koncentrat za otopinu za infuziju zoledronatna kiselina
1Adverse events occurring with frequencies < 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid as indicated in sections 4.1 and 4.2 (see section 4.8) 
Hipofosfatemija 1 Štetni događaji koji nastaju s učestalošću < 5% bili su medicinski procijenjeni i pokazalo se da su u skladu s dobro utvrđenim sigurnosnim profilom zoledronatne kiseline kako je navedeno u dijelovima
Caution is advised when Zoledronic acid Actavis is administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products. 
budući da je uočeno povećanje incidencije osteonekroze čeljusti u bolesnika koji se istodobno liječe tim lijekovima.
Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent. 
Jednokratne i višekratne infuzije zoledronatne kiseline u dozi od 2, 4, 8 i 16 mg u trajanju od 5 i 15
How much Zoledronic acid Actavis is given 
Koliko se Zoledronatne kiseline Actavis daje
BPI mean change from baseline 
Srednja vrijednost promjene u BPI od početne vrijednosti
Tell your doctor immediately if you experience symptoms such as new onset or worsening of aches, pain or stiffness while being treated with Zoledronic acid Actavis or after stopping treatment. 
Zoledronatnom kiselinom Actavis ili nakon prestanka liječenja dobijete simptome kao što su novonastali ili pogoršani bolovi ili ukočenost.
How Zoledronic acid Actavis is given 
Kako se daje Zoledronatna kiselina Actavis
General disorders and administration site conditions Common: 
Opći poremećaji i reakcije na mjestu primjene Vrlo često:
- Do not use Zoledronic acid Actavis after the expiry date stated on the vial and carton after EXP. - This medicinal product does not require any specific storage conditions. 
- Zoledronatna kiselina Actavis se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na bočici i kutiji iza „EXP“.
Tell your doctor and dentist immediately if you experience such symptoms while being treated with Zoledronic acid Actavis or after stopping treatment. 
Ako osjetite ove simptome, za vrijeme ili nakon liječenja Zoledronatnom kiselinom Actavis odmah obavijestite svog liječnika ili zubara.
Placebo Zoledronic acid 
Placebo Zoledronatna kiselina hiperkalcemijom izazvanom tumorom.
The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06-0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose. 
u ispitivanjima jednostruke doze (1,6 mg/kg) i višestrukih doza u trajanju do jednog mjeseca (0,06
Common (may affect up to 1 in 10 people): - Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache. 
- Rijetko može nastati neuobičajen prijelom bedrene kosti osobito u bolesnika koji se dugotrajno liječe zbog osteoporoze; osjetite li bol, slabost ili nelagodu u natkoljenici, kuku ili preponama,
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 
DODATAK I. SAŽETAK OPISA SVOJSTAVA LIJEKA
Proportion of patients with SREs p-value 
Udio bolesnika s koštanim događajem (%)
- Shelf life after dilution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C - 8°C and at 25°C after dilution in 100 ml 0.9% w/v sodium chloride solution or 100 ml 5% w/v glucose. 
0,9%-tne m/V otopine natrijevog klorida ili 100 ml 5%-tne m/V otopine glukoze dokazana je za 24 sata na temperaturi od 2°C do 8°C i na 25°C.
Serum calcium should be measured and hypocalcaemia must be corrected before initiating zoledronic acid therapy. 
Prije uvođenja terapije zoledronatne kiseline potrebno je odrediti razinu kalcija u serumu i korigirati hipokalcemiju.
Zoledronic acid Actavis recommended dose* 
Preporučena doza Zoledronatne kiseline
Pain in extremities, arthralgia, musculoskeletal pain General disorders and administration site conditions Very common: 
Bol u ekstremitetima, artralgija, mišićno-koštana bol
The following information is intended for healthcare professionals only: How to prepare and administer Zoledronic acid Actavis 
Sljedeće informacije namijenjene su samo zdravstvenim radnicima:
While being treated with Zoledronic acid Actavis, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups. 
Za vrijeme liječenja Zoledronatnom kiselinom Actavis, morate održavati dobru oralnu higijenu
- Low level of magnesium and potassium in the blood. 
- Niska razina magnezija i kalija u krvi; liječnik će pratiti ove elektrolite i poduzeti potrebne mjere.
(PAOD Stage II) 
(PAOD stadij II).
Results are heterogeneous and inconsistent. 
Rezultati su raznoliki i nedosljedni.
Available data is in fact indicative of such causal relationship. 
Dostupni podaci zapravo ukazuju na takvu uzročnu povezanost.
The seriousness of such adverse effects and their possible fatal outcome is underlined. 
Istaknuti su ozbiljnost takvih štetnih događaja i njihov mogući smrtonosni ishod.
In six of the evaluable studies with population under 100 patients there were similar findings. 
U 6 procjenjivih ispitivanja s populacijom ispod 100 bolesnika bila su prisutna slična otkrića.
Under-reporting can also be suspected because the substance has been on the market for a long time and because fibrosis is already mentioned as an undesirable effect in the product information. 
Može se također sumnjati i na nedostatno prijavljivanje jer je tvar na tržištu dulje vrijeme i jer se fibroza već spominjala kao neželjeni učinak u informacijama o proizvodu.
• The Committee considered the procedure under Article 31 of Directive 2001/83/EC for ergot derivatives containing medicinal products in the concerned indications. 
• Povjerenstvo je razmatralo postupak iz članka 31. Direktive 2001/83/EZ za lijekove koji sadrže derivate ergota u navedenim indikacijama.
In Europe, dihydroergocristine is also available in combination with etofyllinum. 
U Europi je dihidroergokristin također dostupan u kombinaciji s etofilinom.
In order to lift the suspension, MAHs must identify a specific patient population for which the benefits of the product outweigh the identified risk. 
Kako bi ukinuli suspenziju, nositelji odobrenja trebaju identificirati specifičnu populaciju bolesnika za koje dobrobiti lijeka nadmašuju identificirani rizik.
There were 3 placebo controlled studies with a study population of 200-240 patients. 
Postojala su tri placebom kontrolirana ispitivanja s populacijom ispitanika od 200 do 240 bolesnika.
It produces a decrease in blood pressure and an increase in peripheral blood flow. 
Uzrokuje pad tlaka krvi i povećanje perifernog protoka.
• The Committee is of the opinion that the evidence for clinically significant efficacy of dihydroergocristine in the currently assessed indications is very limited, and therefore the potential benefit for patients in these indications is outweighed by the above identified risk. 
• Povjerenstvo smatra da su dokazi značajne kliničke djelotvornosti dihidroergokristina u trenutno procijenjenim indikacijama vrlo ograničeni i da je stoga moguća dobrobit za bolesnike u ovim indikacijama nadmašena prethodno navedenim rizikom.
Its effect results mainly from its α1-blocking properties. 
Njegovi učinci uglavnom su rezultat blokade α1 receptora.
There are 2 further studies by Hugonot et al with population of 114-127 patients, both showing superiority over placebo. 
Postojala su dva daljnja ispitivanja od strane Hugonota et al s populacijom od 114 do 127 bolesnika i oba su bila superiorna u odnosu na placebo.
• The Committee considered the overall submitted data provided by the MAHs and the outcome of the scientific advisory group. 
• Povjerenstvo je razmatralo ukupne predane podatke koje su dostavili nositelji odobrenja i ishod vijećanja znanstvene, savjetodavne skupine.
Moreover the severity of such adverse effects, their possible fatal outcome and the raised risk for patient to develop a fibrotic disorder with long term use according to the authorised indications should be underlined. 
Štoviše, potrebno je istaknuti ozbiljnost takvih štetnih događaja, njihov mogući smrtonosni ishod i povećani rizik za bolesnike od razvoja fibrotičkog poremećaja uz dugoročnu primjenu u skladu s odobrenim indikacijama.
The CHMP has considered the totality of the available data on the safety and efficacy of dihydroergocristine. 
CHMP je uzeo u obzir ukupne dostupne podatke o sigurnosti i djelotvornosti dihidroergokristina.
A review of all other available data (i.e. literature data, pre-clinical data, and other clinical data including epidemiological studies) that were relevant to evaluate the risk of fibrosis was provided where possible. 
Pregled svih drugih dostupnih podataka (primjerice podataka iz literature, nekliničkih podataka i drugih kliničkih podataka uključujući epidemiološka ispitivanja) koji su bili relevantni za procjenu rizika od fibroze prikazan je kad je to bilo moguće.
Among these 3 studies, the publications by Lazzaroni et al and Aranda et al indicated superiority over placebo, while the study by Vellas et al demonstrated similar efficacy to placebo. 
Od ova tri ispitivanja, publikacije koje su objavili Lazzaroni et al i Aranda ukazale su na superiornost nad placebom dok je ispitivanje od strane Vellasa et al pokazalo sličnu djelotvornost placebu.
Of the 6 randomised, double blind, placebo-controlled studies, 5 studies were not considered relevant by the CHMP because the definition of the diagnosis was not standardised, no primary efficacy criterion was selected among the multi-dimensional assessment, the number of patients per group was small (from 47 to 65), and the treatment duration was short (2 and 3 months). 
Od 6 randomiziranih, dvostruko slijepih, placebom kontroliranih ispitivanja, 5 njih CHMP nije smatrao važnim jer definicija dijagnoze nije bila standardizirana te nije odabran primarni kriterij djelotvornosti, a broj bolesnika po skupini bio je mali (od 47 do 65) te je trajanje liječenja bilo kratko (2 i 3 mjeseca).
Of these, 18 concerned placebocontrolled trials, 2 concerned actively-controlled trials and 7 concerned open label studies. 
Od toga je 18 placebom kontroliranih kliničkih ispitivanja, 2 ispitivanja kontrolirana djelatnom tvari i 7 otvorenih ispitivanja.
The group highlighted that the claimed indication is not used anymore in the clinical practice and that from a clinical viewpoint there is no evidence at present that there is a therapeutic need for this active substance in the treatment of cognitive and neurosensorial impairment in the elderly. 
Skupina je istaknula da se tražene indikacija više ne upotrebljava u kliničkoj praksi i da s kliničkog stajališta nema aktualnog dokaza da postoji terapijska potreba za ovu djelatnu tvar u liječenju kognitivnog i neurosenzorskog oštećenja u starijih.
The CHMP considered the MAHs' proposals for risk minimisation measures. 
CHMP je razmatrao prijedloge nositelja odobrenja za mjere minimizacije rizika.
On 18 January 2012, France triggered a referral under Article 31 of Directive 2001/83/EC for the following ergot derivatives containing medicinal products: dihydroergocryptine/caffeine, dihydroergocristine, dihydroergotamine, dihydroergotoxine and nicergoline. 
Francuska je pokrenula postupak procjene u skladu s člankom 31. Direktive 2001/83/EZ za sljedeće lijekove koji sadrže derivate ergota: dihidrergokriptinin/kofein, dihidroergokristinin, dihidroergotamin, dihidroergotoksin i nikergolin.
The CHMP was of the opinion that no efficacy conclusion could be drawn based on these studies. 
CHMP je smatrao da se na temelju ovih ispitivanja ne mogu donijeti zaključci o djelotvornosti.
Although some of the proposed measures could help identify patients with pre-existing fibrosis, relevant concomitant medication and increased risk, the Committee pointed out that they are insufficient to avoid that some patients develop fibrosis and ergotism during treatment. 
Iako neke od predloženih mjera mogu pomoći u identifikaciji bolesnika s postojećom fibrozom, relevantnih konkomitantnih lijekova i povećanog rizika, Povjerenstvo je istaknulo da nisu dostatne da bi pojedini bolesnici izbjegli fobrozu i ergotizam tijekom liječenja.
• Ancillary treatment of intermittent claudication in symptomatic peripheral arterial occlusive disease 
• Pomoćno liječenje intermitentne klaudikacije kod simptomatske okluzivne bolesti perifernih arterija
• Orthostatic hypotension 
• Ortostatska hipotenzija.
The marketing authorisation holders (MAHs) submitted all available efficacy data from clinical trials and observational studies, including data that became available since the granting of the initial marketing authorisation. 
Nositelji odobrenja za stavljanje lijeka u promet (MAHs) predali su sve dostupne podatke o djelotvornosti iz kliničkih ispitivanja uključujući podatke koji su postali dostupni od dobivanja prvog odobrenja za stavljanje lijeka u promet.
The CHMP also noted the position of one of the MAHs that due to the limitations of the data available, the ocular indicaton cannot be upheld. 
CHMP je također zabilježio stajalište jednog od nositelja odobrenja da zbog ograničenja dostupnih podataka nije moguće zadržati okularnu indikaciju.
Following a national pharmacovigilance review held in 2011 new spontaneous notifications reported with some of those products identified serious cases of fibrosis and ergotism and France considered that this safety concern is not outweighed by the limited evidence of efficacy. 
Nakon državne farmakovigilancijske procjene održane 2011. godine, nova spontana izvješća povezana s nekim od lijekova identificirala su ozbiljne slučajeve fibroze i ergotizma, pa je Francuska smatrala da ovaj sigurnosni problem ne premašuje ograničeni podatak o djelotvornosti.
It is available in combination with raubasine that is an adrenolytic and sympatholytic agent with an inhibitory effect on sympathetic centres. 
Dostupan je u kombinaciji s raubazinom koji je adrenolitički i simpatolitički agens s inhibitornim učinkom na simpatičke centre.
• The suspension of the marketing authorisation for dihydroergocristine containing medicinal products referred to in Annex I in the event that no other indications are approved as part of their marketing authorisation. 
• Suspenzija odobrenja za stavljanje lijeka u promet za lijekove koji sadrže dihidroergokristin odnosi spomenute u Prilogu I. u slučaju da nisu odobrene nikakve dodatne indikacije kao dio njihovog odobrenja za stavljanje u promet.
In addition it has a pharmacological action on the serotoninergic and dopaminergic receptors leading to interesting effects on cerebral metabolism. 
Osim toga ima farmakološko djelovanje na serotoninergične i dopaminergične receptore koji uzrokuju zanimljive učinke na cerebralni metabolizam.
Scientific conclusions and grounds for variation to the terms of the marketing authorisations or suspension of the marketing authorisations, as applicable, taking into consideration the approved indications for each product 
Znanstveni zaključci i razlozi za izmjene uvjeta odobrenja za stavljanje lijeka u promet ili suspenziju odobrenja za stavljanje lijeka u promet uzimajući u obzir odobrene indikacije za svaki proizvod
• The Committee considered that a potential causal association between fibrotic reactions or ergotism and dihydroergocristine cannot be excluded. 
• Povjerenstvo je smatralo da se moguća uzročna povezanost između fibrotičkih reakcija ili ergotizma i dihidroergokristina ne može isključiti.
• Symptomatic treatment of veno-lymphatic insufficiency 
• Simptomatsko liječenje veno-limfatičke insuficijencije.
Dihydroergocristine is a partial agonist of α-adrenoreceptors that decreases the activity of sympathetic centres and is responsible for a peripheral adrenolytic effect with an increased venous wall tone. 
Dihifroergokristin je parcijalni agonist α-adrenoreceptora koji smanjuje aktivnost simpatičkih centara te je odgovor na periferni androlitički učinak s povećanim tonusom stijenke krvnih žila.
Overall, the varying affinity for serotoninergic receptors with the different ergot derivatives and the therapeutic doses used may explain the differences observed for notification rates for the fibrotic reactions. 
Ukupno gledano, promjenjivi afinitet za serotoninergične receptore s različitim derivatima ergota i korištenim terapijskijm dozama može objasniti razlike uočene za stupnjeve notifikacije za fibrotičke reakcije.
The data from the reported cases of fibrosis (n=12) are indicative of the capacity of dihydroergocristine to induce fibrotic reactions, mostly localised in the pulmonary area considering also the improvement of some patients following discontinuation of the product. 
Podaci iz prijavljenih slučajeva fibroze (n=12) ukazuju na sposobnost dihidroergokristina na indukciju reakcije fibroze koje su uglavnom lokalizirane u plućnom području uzimajući također u obzir poboljšanje kod nekih bolesnika nakon prekida terapije lijekom.
However, in this study with adequate methodological quality standard, non-significant difference between dihydroergocristine + raubasine and placebo groups was observed. 
Međutim, u ovom ispitivanju s odgovarajućim metodološkim standardom kvalitete, uočena je beznačajna razlika između skupina koje su primale dihidroergokristin s raubazinom i onih koje su primale placebo.
This is indicative of a causal relationship between fibrosis and dihydroergocristine. 
To ukazuje na uzročnu povezanost između fibroze i dihidroergokristina.
While it is agreed that the medical terminology used nowdays and in the past differs and that the data needs to be assessed bearing this aspect in mind, the clinical symptom of dementia is a result of various pathophysiological processes which makes pooling and comparison of the data difficult, especially when the individual studies used slightly different inclusion criteria. 
Dok je istovremeno zaključeno da je medicinska terminologija koja se koristi danas različita od one koja se koristila nekad i da podatke treba procijeniti imajući i taj aspekt u vidu, klinički simptom demencije je rezultat različitih patofizioloških procesa koji otežavaju grupiranje i usporedbu podataka posebice kod pojedinačnih ispitivanja koja koriste blago različite kriterije uključivanja.
The MAHs also submitted their own overviews and critical summaries of all spontaneous reports of fibrotic reactions (cardiac with or without pulmonary arterial hypertension, pulmonary, pleural, peritoneal, retroperitoneal, etc) and ergotism with their ergot derivatives-containing medicinal products. 
Nositelji odobrenja predali u također svoje preglede i kritička izvješća o fibrotičkim reakcijama (srčane s ili bezhipertenzije plućne arterije, pulmonalne, pleuralne, peritonealne, retroperitonealne i sl) te ergotizam kod lijekova koji sadrže derivate ergota.
A scientific advisory group (SAG) was convened in December 2012 at the request of the CHMP during which the experts discussed, based on their clinical experience, whether this substance plays a role in the symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia). 
Znanstvena savjetodavna skupina (SAG) sazvana je u prosincu 2012. na zahtjev CHMP-a tijekom kojeg su stručnjaci, na temelju svog kliničkog iskustva raspravljali da li tvar igra ulogu u simptomatskom liječenju kroničnog patološkog, kognitivnog i neurosenzorskog oštećenja u starijih (isključujući Alzheimerovu bolesti i druge demencije).
Based on these data and based on the pharmacological plausibility, dihydroergocristine is considered to be associated with fibrotic reactions. 
Na temelju ovih podataka i farmakološke vjerojatnosti, smatra se da je dihidrergokristin povezan s fibrotičkim reakcijama.
The most recent study (Vellas 1998 - Not published) that became available after the granting of the initial marketing autohrisation, uses a standardised definition of diagnosis (patients had to present a moderate memory deficit, with a Mini-Mental Sate Examination MMSE > 25 and a score total > 38 and < 70 on the Mac Nair and Kahn auto-questionnaire assessing the difficulties in daily activities) and defines the primary efficacy criterion a priori (the Mac Nair and Kahn auto-questionnaire and the Gröber and Buschke test). 
Najnovija ispitivanja (Vellas 1998. - nije objavljeno) koja su postala dostupna nakon dobivanja prvog odobrenja za stavljanje lijeka u promet (bolesnici su se prezentirali s umjerenim deficitom memorije, s MMSE (mini pregled mentalnog statusa) većim od 25 i ukupnim rezultatom većim od 38 te manjim od 70 na autoupitniku Mac Naira i Kahna koji procjenjuje poteškoće u svakodnevnim aktivnostima) i apriori definira primarni kriterij djelotvornosti te u skladu s Gröber i Buschkeovim testom).